Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Other Investing Activities

Investing cash flows not reported separately.

Novo Nordisk A/SNYSE: NVO

Other Investing Activities · Q2 FY2026 · quarter ended Jun 2026

Other investing activities dips below year-ago levels

Q2 FY2026 other investing activities of DKK 46M (cash outflow) fell 97.1% year over year, behind the +665.4% change in trailing-twelve-month other investing activities. Sequentially, it fell 90.1% from the prior quarter. Over 3 fiscal years it compounded at +125.7% a year.

Context

  • Other investing activities amounted to 9.7% of revenue in FY2025, up 8.3 pp from a year earlier.
  • Other investing activities grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.1% toward the trailing-twelve-month pace of +665.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 46M-90.1% QoQ
Last fiscal yearDec 2025
-DKK 29.97B+623.1% YoY
LTMJun 2026
-DKK 27.71B+665.4% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.1%——
1 year+623.1%——
3-year CAGR+125.7%——
5-year CAGR——
10-year CAGR——

Other Investing Activities history

DKK · from the cash flow

Latest · FY2025
(29.97B) DKK
Year-over-year change
-623.1%

Other Investing Activities vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +665.4% is the 2nd highest of 10, against a peer median of -10.0%.
  • Other investing activities amounts to 8.4% of revenue for NVO, versus a peer median of 2.8%.
NVO Competitors
Other Investing Activities for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 27.71B DKK+665.4%+125.7%8.4%
SNYSanofiLTM Jun 2026€13.23B EUR+1605.4%+84.9%27.1%
MRKMerck & Co., Inc.LTM Jun 2026$5.56B USD-2315.9%—8.4%
LLYEli Lilly and CompanyLTM Jun 2026$4.54B USD-6.6%+27.8%5.7%
PFEPfizer Inc.LTM Jun 2026$1.77B USD+473.4%-64.8%2.8%
GSKGSK plcLTM Jun 2026£1.62B GBP+221.7%—4.9%
AZNAstraZeneca PLCLTM Sep 2026$697.24M USD-74.1%—1.1%
JNJJohnson & JohnsonLTM Sep 2026$553M USD-77.1%—0.6%
ABBVAbbVie Inc.LTM Jun 2026$172M USD-444.0%—0.3%
AMGNAmgen Inc.LTM Jun 2026$36M USD-10.0%+38.7%0.1%
Peer median (excluding NVO) —-10.0%+33.2%2.8%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.